CHICAGO--(BUSINESS WIRE)--Levo Therapeutics, Inc., a biotechnology company dedicated to using genetic insights to advance treatments for Prader-Willi syndrome (PWS) and related disorders, announced ...
Soleno Therapeutics' DCCR shows promising results in reducing hyperphagia in PWS patients. I believe its FDA approval is likely by December 27, 2024. DCCR could become the first approved treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback